Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease

Han,Kun; Jia,Ning; Li,Ji; Yang,Li; Min,Lian-Qiu

doi:10.3892/mmr.2013.1601

Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease

Authors:
- Kun Han
- Ning Jia
- Ji Li
- Li Yang
- Lian-Qiu Min
View Affiliations

Affiliations: Department of Neurology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: July 25, 2013 https://doi.org/10.3892/mmr.2013.1601
Pages: 737-740
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to investigate the effects of varying doses of caffeine on memory impairment and the expression of brain neurotrophic derived factor (BNDF) and TrkB in PS1/APP double transgenic mouse models. PS1/APP double transgenic mice were administered 0.3 ml/day of saline, 1.5 mg/day of caffeine or 0.75 mg/day of caffeine for eight weeks. A water maze test and western blotting were used to determine the memory capability and expression of hippocampal BNDF and TrkB of the mice. The results demonstrated that 0.75 mg/day and 1.5 mg/day doses of caffeine significantly increased memory capability and the expression of hippocampal BDNF and TrkB in PS1/APP mice with a dose-response effect. The results suggested that chronic caffeine treatment may reverse memory impairment in PS1/APP transgenic mice, and BDNF and its receptor TrkB, may be involved in this process.

View Figures

View References

1	Massoud F and Gauthier S: Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol. 1:69–80. 2010.
2	Ritter JM: Drugs for Alzheimer’s disease. Brit J Clin Pharmacol. 4:501–503. 2012.
3	Fisone G, Borgkvist A and Usiello A: Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 7:857–872. 2004. View Article : Google Scholar : PubMed/NCBI
4	Ritchie K, Carrière I, de Mendonca A, et al: The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 69:536–545. 2007. View Article : Google Scholar : PubMed/NCBI
5	Santos C, Lunet N, Azevedo A, et al: Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheimers Dis. 20:S175–S185. 2010.PubMed/NCBI
6	Maia L and de Mendonça A: Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol. 9:377–382. 2002.
7	Arendash GW, Mori T, Cao C, et al: Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimers Dis. 17:661–680. 2009.PubMed/NCBI
8	Arendash G, Schleif W, Rezai-Zadeh K, et al: Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain (beta)-amyloid production. Neuroscience. 142:941–952. 2006.
9	Bekinschtein P, Cammarota M, Igaz LM, et al: Persistence of long-term memory storage requires a late protein synthesis-and BDNF-dependent phase in the hippocampus. Neuron. 53:261–277. 2007. View Article : Google Scholar : PubMed/NCBI
10	Peng S, Wuu J, Mufson EJ and Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 93:1412–1421. 2005.PubMed/NCBI
11	Ferrer I, Marín C, Rey MJ, et al: BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 58:729–739. 1999. View Article : Google Scholar : PubMed/NCBI
12	Kemppainen S, Rantamäki T, Jerónimo-Santos A, et al: Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging. 33:e23–e39. 2011.PubMed/NCBI
13	Lynch G, Kramar EA, Rex CS, et al: Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. J Neurosci. 27:4424–4434. 2007.PubMed/NCBI
14	Zeitlin R, Patel S, Burgess S, et al: Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer’s transgenic mice. Brain Res. 1417:127–136. 2011.PubMed/NCBI
15	Prasanthi JR, Dasari B, Marwarha G, et al: Caffeine protects against oxidative stress and Alzheimer’s disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med. 49:1212–1220. 2010.PubMed/NCBI
16	Alhaider IA, Aleisa AM, Tran TT, et al: Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity. Sleep. 33:437–444. 2010.PubMed/NCBI
17	Cao C, Wang L, Lin X, et al: Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis. 25:323–335. 2011.PubMed/NCBI
18	Nagahara AH, Merrill DA, Coppola G, et al: Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med. 15:331–337. 2009.